A report published by visiongain in May 2016 forecasts that overall world revenues of next-generation biological drugs will reach $21.31 billion in 2020. Sales growth will continue through to 2026, especially with the entrance of more companies and advances in biopharmaceutical technology. That revenue prediction and others appear in Next-Generation Biologics Market 2016-2026: Revenue Forecasts and R&D Trends for Therapeutic Antibody Technologies, Insulins, Growth Hormones, Recombinant Coagulation Factors and Regenerative Medicine.

That study’s producer, visiongain, is a business information publisher and consultancy in London, UK. That company helps organisations assess commercial prospects of industries and markets in healthcare and other fields.

The updated study analyses events, prospects and sales opportunities shaping the development, production and marketing of next-generation biologics. That investigation shows multilevel revenue forecasting to 2026 and qualitative assessments. The work explores activities of companies providing next-generation biologics, assessing their commercial potentials. The next-generation biologics market holds many opportunities from 2016, including rising sales in developed and developing countries.

Visiongain’s updated study predicts that the global next-generation biologics market will continue to expand its revenues from 2016 to 2026. That sales growth is mainly driven by the rising incidence and prevalence of chronic diseases, which will drive demand for new and improved biologics in developed and emerging national markets.

Aanchal Verma, a pharmaceutical industry analyst in visiongain, said: “Next-generation biologic therapies are newer treatments providing novel alternatives to the first-generation biological drugs. With more and more first-generation biologics facing patent expiry, pharmaceutical companies are focusing their resources to innovate and improve technology for production of next-generation biologics. The launch of those medicines will help balance revenue losses from biosimilar drugs.

“The biologics market has been extremely profitable, with combined revenues from the top ten best-selling biologic drugs amounting to $74bn in 2015. The next-generation biologics market is set to experience strong revenue growth during our forecasted period, with their demand driven by the rising incidence and prevalence of chronic diseases globally. That market possesses an extensive R&D pipeline, with many candidates progressing to late-stage clinical trials, which will further propel the market in the coming 10 years.”

Visiongain’s updated analysis shows revenue forecasts to 2026 at overall world, submarket, product and national level. First it gives revenue predictions to 2026 for therapeutic submarkets at world level:

• Next-generation antibody therapies, including the subsectors of antibody-drug conjugates (ADCs), engineered antibodies and bispecific treatments

• Next-generation antibody fragments and antibody-like proteins (ALPs)

• Next-generation insulins, including submarkets assessing oral insulins, ultra-long and ultra-rapid acting therapies

• Next-generation recombinant coagulation factors

• Next-generation growth hormones

• Regenerative medicine, including tissue engineering, gene therapies and stem cells.

The new report also gives revenue forecasts for eight leading drugs in that field: Kadcyla, Adcetris, Tresiba, Alprolix, Eloctate, Gazyva/Gazyvaro, Plegridy and Afrezza. Research, data and analyses cover activities of Novo Nordisk, Eli Lilly, Bayer, Sanofi, Pfizer and other developers, manufacturers and marketers of those follow-on biological medicines. That investigation also reviews pharmaceutical companies’ research and development for next-generation biomedicines.

That study also discusses other commercial news, shows four research interviews and predicts revenues to 2026 in nine leading national markets. The work analyses the US, Japan, Germany, the UK, Italy, Spain, France, China and India.

Next-Generation Biologics Market 2016-2026 adds to visiongain’s analyses of industries and markets in healthcare. Together those studies cover pharmaceuticals, diagnostics, medical devices, outsourced services and biotechnologies.